Bristol-Myers Squibb Overview
Latest ROE for Bristol-Myers Squibb: 41.59% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow41.59%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Bristol-Myers Squibb posts a ROE of 41.59%. That is above the Healthcare sector average of 29.33%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For Healthcare stocks, a ROE near 29.33% is typical. Bristol-Myers Squibb's 41.59% is higher that level. That is roughly 41.8% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Bristol-Myers Squibb's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 41.59%; use YoY and peer views to separate noise from signal.
Context for BMY's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 29.33%), and (3) consistency with growth and profitability. This page covers the first two; Bristol-Myers Squibb's other metric pages and overview cover the third.
Judging Bristol-Myers Squibb against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with 41.59% here, then scan peer and history charts to see if the gap is persistent.
